Skip to main content

Get the latest public health information from CDC

Clinicalinfo.HIV.gov logo.
In affiliation with HIV.gov
Main navigation
  • Home
  • About
  • Guidelines
  • Drug Database
  • Glossary
  • News
  • Mobile Application
  • Resources
  • Contact Us
  • English
  • Español (Spanish)
  1. Home
  2. Guidelines
  3. HIV Clinical Guidelines: Pediatric ARV
  4. Overview

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Search Guidelines

  • Archived Guidelines (1)
  • Guidance for COVID-19 and People with HIV (2)
  • Guidelines for Caring for Persons with HIV in Disaster Areas (4)
  • HIV Clinical Guidelines: Adult and Adolescent ARV (18)
  • HIV Clinical Guidelines: Adult and Adolescent Opportunistic Infections (34)
  • HIV Clinical Guidelines: Pediatric ARV (19)
  • HIV Clinical Guidelines: Pediatric Opportunistic Infections (32)
  • Perinatal HIV Clinical Guidelines (18)
Version:
Brief Full
What's New Guidelines Panel Members Financial Disclosure Introduction Maternal HIV Testing and Identification of Perinatal HIV Exposure Infant Feeding for Individuals with HIV in the United States Diagnosis of HIV in Infants and Children Clinical and Laboratory Monitoring of Pediatric HIV Infection When to Initiate Therapy in Antiretroviral-Naive Children
What to Start: Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children
What Not to Start: Regimens Not Recommended for Use in Antiretroviral-Naive Children
Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection Special Considerations for Antiretroviral Therapy Use in Adolescents with HIV Adherence to Antiretroviral Therapy in Children and Adolescents with HIV
Overview
CNS Toxicity
Dyslipidemia
Gastrointestinal Effects
Hematologic Effects
Hepatic Events
Insulin Resistance, Asymptomatic Hyperglycemia, Diabetes Mellitus
Lactic Acidosis
Lipodystrophies and Weight Gain
Nephrotoxic Effects
Osteopenia and Osteoporosis
Rash and Hypersensitivity Reactions
Overview
Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy
Recognizing and Managing Antiretroviral Treatment Failure
Antiretroviral Treatment Interruption in Children with HIV
Overview
Abacavir
Emtricitabine
Lamivudine
Tenofovir AF
Tenofovir DF
Zidovudine
Doravirine
Efavirenz
Etravirine
Nevirapine
Rilpivirine
Atazanavir
Darunavir
Lopinavir/Ritonavir
Fostemsavir
Ibalizumab
Maraviroc
Bictegravir
Cabotegravir
Dolutegravir
Elvitegravir
Raltegravir
Cobicistat
Ritonavir
Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class
Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents
Overview
Didanosine
Enfuvirtide
Fosamprenavir
Indinavir
Nelfinavir
Saquinavir
Stavudine
Tipranavir
Drug Abbreviations
General Terms
Study and Trial Names
Appendix C: CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Diseases Categorization Appendix D: Supplemental Information

Download Guidelines

  • Section OnlyPDF (101.95 KB)
  • Full GuidelinePDF (6.69 MB)
  • Recommendations OnlyPDF (387.7 KB)
  • Tables OnlyPDF (1.02 MB)
  • Drug Tables OnlyPDF (2.74 MB)

Related Content

  • Clinicalinfo Drug Database
  • HIVinfo Fact Sheets: HIV and Children and Adolescents
  • HIVinfo Infographics
  • AETC National HIV Curriculum
  • How to Cite These Guidelines
  • Pediatric ARV Archived Guidelines

Appendix A: Pediatric Antiretroviral Drug Information

Overview

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTIs)

Abacavir
Emtricitabine
Lamivudine
Tenofovir alafenamide
Tenofovir disoproxil fumarate
Zidovudine

Non-Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)

Doravirine
Efavirenz
Etravirine
Nevirapine
Rilpivirine

Protease Inhibitors (PIs)

Atazanavir
Darunavir
Lopinavir/Ritonavir

Entry and Fusion Inhibitors

Fostemsavir
Ibalizumab
Maraviroc

Integrase Inhibitors (INSTIs)

Bictegravir
Cabotegravir 
Dolutegravir
Elvitegravir
Raltegravir

Pharmacokinetic Enhancers

Cobicistat
Ritonavir

Fixed-Dose Combinations

Antiretrovirals Available in Fixed-Dose Combination Tablets
Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents

Archived Drugs

Didanosine
Enfuvirtide
Fosamprenavir
Indinavir
Nelfinavir
Saquinavir
Stavudine
Tipranavir

Download Guidelines

  • Section OnlyPDF (101.95 KB)
  • Full GuidelinePDF (6.69 MB)
  • Recommendations OnlyPDF (387.7 KB)
  • Tables OnlyPDF (1.02 MB)
  • Drug Tables OnlyPDF (2.74 MB)

Related Content

  • Clinicalinfo Drug Database
  • HIVinfo Fact Sheets: HIV and Children and Adolescents
  • HIVinfo Infographics
  • AETC National HIV Curriculum
  • How to Cite These Guidelines
  • Pediatric ARV Archived Guidelines

CONNECT WITH US

Facebook
Twitter
Instagram
Email Updates

Footer menu

  • Home
  • About
  • Guidelines
  • Drug Database
  • Glossary
  • News
  • Mobile Application
  • Resources
  • Contact Us
  • Privacy Policy
  • Sponsors
  • Nondiscrimination Notice
  • Disclaimers
  • Accessibility
  • HHS Vulnerability Disclosure

External links

  • HIVinfo.NIH.gov
  • HHS.gov
  • NIH.gov
  • Players & Viewers
  • HHS 508
  • HHS Privacy Policy
  • Whitehouse.gov
  • USA.gov
  • Freedom of Information Act

Provided in collaboration with NIH’s Office of AIDS Research.